Date: Wednesday 29 Aug 2012
LONDON (ShareCast) - 888 Holdings: Investec upgrades from sell to buy target hiked from 18p to 95p.
Advanced Medical Solutions: Singer Capital Markets upgrades to buy, target lifted from 80p to 82p.
AstraZeneca: AlphaValue downgrades to reduce.
Bunzl: Jefferies raises target from 835p to 860p, underperform rating kept.
Cairn Energy: HB Markets downgrades to hold.
G4S: HB Markets downgrades to sell; Jeffferies cuts tagged from 285p to 275p, hold rating kept.
Immunodiagnostic Systems: Investec cuts target from 450p to 354p, buy rating kept.
Lamprell: Investec keeps hold rating and 100p target.
Marks & Spencer: Investec keeps sell rating and 275p target.
Meggitt: AlphaValue upgrades to add.
Morrison: Jefferies maintains buy rating and 350p target.
Petrofac: Investec reiterates hold rating and 1,500p target.
Reckitt Benckiser: AlphaValue downgrades to add, target cut from 4,305.2p to 4,162.8p.
Reed Elsevier: JPMorgan Cazenove upgrades to overweight.
Regus: Jefferies maintains buy rating and 130p target.
SSE: Bank of America-Merrill Lynch upgrades to buy from neutral.
Centrica: Bank of America-Merrill Lynch downgrades to underperform from neutral.
Shire: AlphaValue downgrades to add, target cut from 2,306.9p to 2,217.4p.
Travis Perkins: Jefferies downgrades to hold, target cut from 1,200p to 1,120p.
BC
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 210.50p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 258.00p |
52 Week Low | 177.20p |
Volume | 0 |
Shares Issued | 217.41m |
Market Cap | £457.65m |
RiskGrade | 156 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 4 |
Buy | 2 |
Neutral | 2 |
Sell | 1 |
Strong Sell | 0 |
Total | 9 |
Latest | Previous | |
---|---|---|
Final | Interim | |
Ex-Div | 30-May-24 | 28-Sep-23 |
Paid | 21-Jun-24 | 27-Oct-23 |
Amount | 1.66p | 0.70p |
Time | Volume / Share Price |
0 @ 0.000p |
CEO | A Christopher (Chris) Meredith |
CFO | Eddie Johnson |
Chair | Liz Shanahan |
You are here: research